Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

News Focus

SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > This is not the news IIROC halted KLY..IMO!

<< Previous

Bullboard Posts

Next >>

Comment by MyKnighton May 19, 2020 10:06am

101 Views

Post# 31045486

RE:RE:This is not the news IIROC halted KLY..IMO!

Exactly, expect the news coming to be the one we been waiting for a while....

RE:This is not the news IIROC halted KLY..IMO!

ETalien wrote:FDA fast track! Imo!

... no trade resumption... it does look like more news on the way ...